<?xml version="1.0" encoding="UTF-8"?>
<p id="par0090">CanSino Biologicals started Phase 2 clinical trial in China (NCT04341389) for Ad5- nCoV which showed safe, tolerable and immunogenic in phase 1 clinical trial. Moderna Announces Positive Interim Phase 1 Data for mRNA-1273 vaccine. The vaccine elicited virus- neutralizing antibodies at the levels displayed in convalescent sera and showed full protection against viral replication in the lungs in a mouse model. The vaccine candidate mRNA-1273 also showed safe and well tolerated.</p>
